image
Healthcare - Medical - Devices - NASDAQ - US
$ 3.92
-5.54 %
$ 3.33 M
Market Cap
-0.78
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TIVC stock under the worst case scenario is HIDDEN Compared to the current market price of 3.92 USD, Tivic Health Systems, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TIVC stock under the base case scenario is HIDDEN Compared to the current market price of 3.92 USD, Tivic Health Systems, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one TIVC stock under the best case scenario is HIDDEN Compared to the current market price of 3.92 USD, Tivic Health Systems, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TIVC

image
$14.0$14.0$12.0$12.0$10.0$10.0$8.0$8.0$6.0$6.0$4.0$4.0$2.0$2.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
780 K REVENUE
-33.67%
-5.66 M OPERATING INCOME
31.34%
-5.66 M NET INCOME
31.40%
-5.72 M OPERATING CASH FLOW
32.73%
0 INVESTING CASH FLOW
100.00%
4.33 M FINANCING CASH FLOW
-49.08%
70 K REVENUE
-61.11%
-1.51 M OPERATING INCOME
2.40%
-1.5 M NET INCOME
-1.69%
-889 K OPERATING CASH FLOW
34.87%
-526 K INVESTING CASH FLOW
0.00%
82 K FINANCING CASH FLOW
-93.04%
Balance Sheet Tivic Health Systems, Inc.
image
Current Assets 2.64 M
Cash & Short-Term Investments 2 M
Receivables 69 K
Other Current Assets 568 K
Non-Current Assets 168 K
Long-Term Investments 0
PP&E 119 K
Other Non-Current Assets 49 K
71.32 %20.24 %4.24 %Total Assets$2.8m
Current Liabilities 272 K
Accounts Payable 125 K
Short-Term Debt 0
Other Current Liabilities 147 K
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
45.96 %54.04 %Total Liabilities$272.0k
EFFICIENCY
Earnings Waterfall Tivic Health Systems, Inc.
image
Revenue 780 K
Cost Of Revenue 778 K
Gross Profit 2 K
Operating Expenses 5.66 M
Operating Income -5.66 M
Other Expenses -6 K
Net Income -5.66 M
1m1m00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)780k(778k)2k(6m)(6m)6k(6m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.26% GROSS MARGIN
0.26%
-725.77% OPERATING MARGIN
-725.77%
-725.00% NET MARGIN
-725.00%
-223.08% ROE
-223.08%
-201.46% ROA
-201.46%
-223.31% ROIC
-223.31%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Tivic Health Systems, Inc.
image
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)(9m)(9m)202020202021202120222022202320232024202420252025
Net Income -5.66 M
Depreciation & Amortization 352 K
Capital Expenditures 0
Stock-Based Compensation 229 K
Change in Working Capital -1 M
Others -251 K
Free Cash Flow -5.72 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Tivic Health Systems, Inc.
image
TIVC has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Tivic Health Systems, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Tivic Health Systems Inc. (TIVC) Q1 2025 Earnings Call Transcript Tivic Health Systems Inc. (NASDAQ:TIVC ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Jennifer Ernst – Chief Executive Officer Lisa Wolf – Interim Chief Financial Officer Michael Handley – Chief Operating Officer and President-Tivic Biopharma Division Conference Call Participants Operator Welcome to Tivic Health Systems First Quarter 2025 Financial Results and Operational Update Conference Call. This call has been prerecorded, and the questions you have submitted in advance will be answered following the prepared remarks. seekingalpha.com - 1 month ago
Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2025 and outlined operational highlights based on its newly expanded clinical pipeline. “This is a defining time for the company. During the quarter we initiated a significant strategic shift, dramatically expanding Tivic's clinical pipeline for restoring immune system health," stated Tivic CEO Jennifer Er. businesswire.com - 1 month ago
Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food & Drug Administration. Scorpius BioManufacturing, Inc. businesswire.com - 1 month ago
Tivic Expands VNS Intellectual Property Portfolio FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today it is expanding its non-invasive VNS patent portfolio with the filing of a new patent application with the United States Patent and Trademark Office. Patent No. 63,801,058 entitled “Vagus Nerve Stimulation System” expands the claims and protection around the technology that Tivic is developing and which it expects will redefine state-of-the art in non-invasive vagus. businesswire.com - 1 month ago
Tivic Health to Report First Quarter 2025 Financial Results on May 15th Via Conference Call and Webcast FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its first quarter results for 2025 via pre-recorded conference call and webcast on Thursday, May 15, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID: 13753498 Webcast Li. businesswire.com - 1 month ago
Tivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of Its Product Candidates FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that it provided briefings to senior leadership at the White House and FDA which garnered significant positive interest in potential military and defense applications for its biologic and bioelectronic product candidates. Both meetings were held in Washington, D.C. on April 17th. The U.S. Government, through agencies including BARDA, NASA, Defense Threats Reduction A. businesswire.com - 1 month ago
Tivic Health Extends its Worldwide License of TLR5 Agonist Entolimod to Include the Treatment of Neutropenia FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced that, on March 28, 2025, it exercised its licensing option for the exclusive, worldwide rights to advance Entolimod™ for a second indication, Neutropenia. This expansion of commercial rights is part of the license agreement with Statera Biopharma for its late-stage Toll-like Receptor 5 (TLR5) immunotherapy program Entolimod™. Neutropenia is a condition characterized b. businesswire.com - 2 months ago
Tivic Health Systems, Inc. Regains Compliance with NASDAQ Minimum Bid Price Listing Rule FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today that it has received confirmation from Nasdaq that the Company has regained compliance with the minimum bid requirements of Nasdaq Listing Rule 5550(a)(2). Consequently, Tivic Health's common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol “TIVC.” About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics com. businesswire.com - 2 months ago
Tivic Health Systems, Inc. (TIVC) Q4 2024 Earnings Call Transcript Tivic Health Systems, Inc. (NASDAQ:TIVC ) Q4 2024 Results Conference Call March 21, 2025 4:30 PM ET Company Participants Jennifer Ernst - Chief Executive Officer Lisa Wolf - Interim Chief Financial Officer Operator Welcome to Tivic Health Systems Year-End 2024 Financial Results and Operational Update Conference Call. This call has been prerecorded and the questions you have submitted in advance will be answered following prepared remarks. seekingalpha.com - 2 months ago
Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, today announced year end December 31, 2024 financial results, highlighted key developments in its clinical program expansion and discussed progress made across the company's operations. “The important strategic events of the past several months have been nothing short of transformative,” stated Tivic Health Chief Executive Officer, Jennifer Ernst. “We have successfully reshaped the. businesswire.com - 2 months ago
Tivic Health to Report 2024 Year-End Financial Results on March 21st Via Conference Call and Webcast FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health, today announced that it will report its year-end financial results for 2024 via pre-recorded conference call and webcast on Friday, March 21, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 1-877-407-0779 International: 1-201-389-0914 Conference ID. businesswire.com - 3 months ago
Tivic Health and Feinstein Institute Present New Data Showing Personalized Vagus Nerve Stimulation Method Optimizes Impact on Autonomic Nervous System FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today new data that shows personalizing its non-invasive vagus nerve stimulation (ncVNS) method optimized the stimulation's impact on autonomic nervous system activity. Tivic Health believes these findings strongly support its strategy to develop highly personalized neuromodulation devices that can better address inflammatory, cardiac and neurologic disorders compared to c. businesswire.com - 3 months ago
8. Profile Summary

Tivic Health Systems, Inc. TIVC

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 3.33 M
Dividend Yield 0.00%
Description Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
Contact 25821 Industrial Boulevard, Fremont, CA, 94545 https://www.tivichealth.com
IPO Date Nov. 11, 2021
Employees 7
Officers Ms. Jennifer Ernst Co-Founder, Chief Executive Officer & Director Mr. Michael Kevin Handley Chief Operating Officer & President of Tivic Biopharma Ms. Lisa G. Wolf Interim Chief Financial Officer Dr. Blake Gurfein Ph.D. Chief Scientific Officer